HC Wainwright Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 147.00% from the company’s previous close.

STOK has been the subject of a number of other reports. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 target price on shares of Stoke Therapeutics in a research note on Friday, February 16th. Canaccord Genuity Group raised their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.63.

Stoke Therapeutics Price Performance

Shares of STOK opened at $14.17 on Tuesday. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The company has a market capitalization of $632.69 million, a price-to-earnings ratio of -5.98 and a beta of 0.68. The business has a 50-day moving average of $5.88 and a 200-day moving average of $4.95.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the transaction, the chief executive officer now owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at approximately $126,550.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,615 shares of company stock valued at $212,852. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in Stoke Therapeutics by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock worth $1,320,000 after acquiring an additional 837 shares during the period. American International Group Inc. lifted its holdings in Stoke Therapeutics by 10.9% during the second quarter. American International Group Inc. now owns 10,506 shares of the company’s stock worth $139,000 after acquiring an additional 1,029 shares during the period. Great West Life Assurance Co. Can lifted its holdings in Stoke Therapeutics by 46.7% during the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after acquiring an additional 1,078 shares during the period. Ensign Peak Advisors Inc bought a new stake in Stoke Therapeutics during the first quarter worth $25,000. Finally, Point72 Hong Kong Ltd bought a new stake in Stoke Therapeutics during the first quarter worth $27,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.